Zhong Ling

Dr. Zhong Ling


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Medicine
Verified
Journal Article
Open access
CXChunbao Xie
Chunbao Xie
JLJiangrong Luo
Jiangrong Luo
YHYangjun Bd He
Yangjun Bd He
LJLingxi Jiang
Lingxi Jiang
ZLZhong Ling
Zhong Ling
YSYi Shi
Yi Shi
Breast cancer susceptibility gene 2 (BRCA2) is the main gene associated with hereditary breast cancers. However, a mutation in BRCA2 has also been found in other tumors, such as ovarian, pancreatic, thyroid, gastric, laryngeal, and prostate cancers. In this review, we discuss the biological functions of BRCA2 and the role of BRCA2 mutations in tumor progression and therapy.

6 May 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
DYDongke Yu
Dongke Yu
YXYu Xiang
Yu Xiang
TGTingting Gou
Tingting Gou
RTRongsheng Tong
Rongsheng Tong
CXChuan Xu
Chuan Xu
JSJianyou Shi
Jianyou Shi

27 September 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MCMin Chen
Min Chen
LCLinxuan Cai
Linxuan Cai
YXYu Xiang
Yu Xiang
ZLZhong Ling
Zhong Ling
JSJianyou Shi
Jianyou Shi

1 October 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
FWFuyu Wang
Fuyu Wang
YLYating Li
Yating Li
LBLan Bai
Lan Bai
WXWenjing Xiao
Wenjing Xiao
ZLZhong Ling
Zhong Ling
JSJianyou Shi
Jianyou Shi

22 January 2026 in Cancer Research
Verified
Journal Article
Closed access
QLQianshi Liu
Qianshi Liu
YLYiqiang Liu
Yiqiang Liu
YZYue Zhou
Yue Zhou
LLLiang Liang
Liang Liang
YWYejian Wan
Yejian Wan
JCJie Chen
Jie Chen
Although surgical resection is an effective intervention for early-stage hepatocellular carcinoma (HCC), postoperative recurrence remains a major clinical hurdle. Delving into the mechanisms underlying relapse and pinpointing potential therapeutic targets are imperative for improving outcomes for patients with HCC. By comparing the microbiota composition in patients with early- and non-relapsing HCC, we identified that Lactobacillus was enriched in patients with relapse-free HCC, serving as an independent prognostic predictor of disease-free survival. Higher levels of intratumoral Lactobacillus johnsonii correlated with an increased abundance of IFNγ+PD-1+CD8+ T cells. Single-cell RNA sequencing, transcriptomic profiling of intratumoral CD45+ immune cells, and in vitro functional assays demonstrated that L. johnsonii preferentially enhanced this cytotoxic-exhausted T-cell population. Nicotinic acid (NA) served as a key metabolite derived from L. johnsonii that expanded IFNγ+PD-1+CD8+ T cells and upregulated effector (granzyme B) and exhaustion (CTLA4) markers. Mechanistically, both L. johnsonii and NA activated the NF-κB pathway, leading to increased IFNγ production and upregulation of the transcription factor NR4A2, which in turn sustained PD-1 expression on CD8+ T cells. Combining L. johnsonii or NA with anti–PD-1 therapy synergistically inhibited tumor relapse and tumor growth in immunocompetent or humanized mice. Crucially, the antitumor efficacy of L. johnsonii was CD8+ T cell–dependent, as depletion abolished its activity. This work unveils a mechanism by which L. johnsonii and its metabolite NA enrich intratumoral IFNγ+PD-1+CD8+ T cells, thereby reshaping the immune microenvironment to potentiate immunotherapy efficacy and suppress HCC recurrence. Significance: Lactobacillus johnsonii produces nicotinic acid that expands intratumoral IFNγ+PD-1+CD8+ T cells, which prevents hepatocellular carcinoma relapse and enhances the efficacy of anti-PD-1 therapy.

16 October 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GTGuoyuan Tang
Guoyuan Tang
SHShan Huang
Shan Huang
JLJi Luo
Ji Luo
YWYingmiao Wu
Yingmiao Wu
SZShuai Zheng
Shuai Zheng
JSJianyou Shi
Jianyou Shi